THIRD-PARTY REVIEW PILOT'S POTENTIAL LONG-TERM BENEFITS JUSTIFY COMPANY PARTICIPATION, FDA'S PHILLIPS SAYS; DEVICE INDUSTRY REPS CRITICIZE PILOT PROGRAM
This article was originally published in The Gray Sheet
Manufacturers should look to the potential long-term benefits of a third-party device review pilot in deciding whether to participate in the program, Philip Phillips, deputy director of the Office of Device Evaluation in FDA's Center for Devices and Radiological Health, said Sept. 9 at the Regulatory Affairs Professionals Society annual meeting in Washington, D.C.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.